Call for Papers

AI and Automation (A2) in Multiplexing Cellular and Tissue Imaging

Special issue in SLAS Technology – completed manuscripts accepted until March 1, 2023!

Submit Manuscript 

SLAS Technology Guest Editors Joe Yeong, (Group Leader Singapore General Hospital), Loo Lit-Hsin, (Senior PI, Bioinformatic Institute, A*STAR), and Colt Egelston, (Assistant Research Professor, City of Hope National Medical Center), invite the submission of abstracts relating to AI and Automation (A2) in cellular and tissue imaging for publication in a 2023 Special Issue.

SLAS Technology is seeking high-quality, short- or full-length research reports, reviews, and perspectives related to AI and Automation (A2) in cellular and tissue imaging. This includes the A2 perspectives of multiplex IHC/IF, spatial transcriptomics & proteomics, high-throughput screening, cell painting and other relevant topics. Manuscripts are welcome from academia, industry, and vendors. Areas of particular interest include: 

  • Analytic pipeline and algorithm of multiplex imaging assays 
  • Automation, standardization and upscaling the throughput of multiplex imaging assays 
  • High-dimensional analysis of multiplex imaging assays  
  • Biomarkers discovery by using multiplex imaging assays 
  • Spatial information of tumor immune micro-environment by using multiplex imaging assays 
  • Immuno-phenotyping by using multiplex imaging assays
  • Technical reproducibility of multiplex imaging assays
  • Comparison of multiplex imaging assays with other modalities such as conventional IHC, RNAseq, NanoString
  • Comparison of two or more multiplex imaging assays techniques (e.g. DNA barcoding vs fluorescence vs metal-conjugation) 
  • Clinical application and translation of biomarkers with multiplex imaging assays

Submit your manuscript before March 1, 2023.  

All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Technology Special Issue.

Publication note: After submissions are accepted, they are typically published online ahead-of-print within 30 days and become immediately searchable and citable with a DOI. 

Questions? Please e-mail ajump@slas.org or call +1.630.256.7527, ext. 106.

Advancement of Diverse RNA-Targeting Modalities

Special issue in SLAS Discovery – completed manuscripts accepted until May 15, 2023!

Submit Manuscript

SLAS Discovery Guest Editor(s) Matthew Disney, Ph.D. (The Scripps Research Institute), and Helen Lightfoot, Ph.D. (AstraZeneca), invite the submission of abstracts covering topics around the identification and optimization of RNA targeting modalities for publication in a 2023 Special Issue. Manuscript abstracts will be used to select and invite papers for review and publication consideration.

SLAS Discovery seeks high-quality, short-or full-length research reports, reviews, protocols and perspectives related to discovery phase identification and scale profiling of modalities targeting RNA. Manuscripts are welcome from academia, industry and vendors. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery Special Issue. Areas of particular interest include, but are not limited to:

  • Screening platforms identifying small molecules targeting RNA (smRNA)  
  • Data analysis and/or computational protocols for smRNA high-throughput screening data including chemistry deep learning and AI approaches 
  • RNA kinetics, dynamics and modifications, and their application for smRNA drug discovery 
  • Approaches for identification of smRNA targets  
  • smRNA target engagement approaches
  • Translational investigations between smRNA in vitro and in cell hit identification/validation approaches 
  • Secondary Pharmacology (screening – wet lab or virtual) investigations into smRNA 
  • Methods for identification and validation (preclinical and/or clinical) of direct smRNA targeting relevant biomarkers 
  • Structure-guided approaches to smRNA directed drug discovery including computational methodologies as well as experimental techniques  
  • Approaches for identification and optimization of RNA degraders (i.e. RIBOTACS)
  • High-content RNA directed methodologies 
  • Examples of successful smRNA and RNA degrader drug discovery efforts and challenges  
  • Screening platforms identifying oligonucleotides targeting RNA 
  • Structure-directed off-target evaluations of oligonucleotides targeting RNA 
  • Approaches to identify and optimize small molecules which modulate proteins directly involved in RNA processing (for example, RNA methylation, adenylation, uridylation)

Submit your completed manuscript before May 15, 2023.